What is claimed:

1. A method for use of lasmiditan in simultaneous, separate, or sequential combination with a calcitonin gene-related peptide (CGRP) antagonist in the treatment of migraine in a patient.

2. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of migraine in a patient.

3. A method for use of lasmiditan in simultaneous, separate, or sequential combination with a calcitonin gene-related peptide (CGRP) antagonist in the treatment of migraine in a patient inadequately controlled by lasmiditan or a CGRP antagonist therapy alone.

4. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of migraine in a patient inadequately controlled by lasmiditan or galcanezumab therapy alone.

5. A method for use of lasmiditan in simultaneous, separate, or sequential combination with a calcitonin gene-related peptide (CGRP) antagonist in the treatment of migraine in a patient suffering from therapy resistant migraine wherein the patients migraines have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

6. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of migraine in a patient suffering from therapy resistant migraine wherein the patients migraines have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

7. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

8. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

9. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once or twice a day.

10. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

11. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

12. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once or twice a day.

13. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once a day.

14. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once a day.

15. A method of any one of claims 2, 4, or 6, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.

16. A method for use of lasmiditan in simultaneous, separate, or sequential combination with a calcitonin gene-related peptide (CGRP) antagonist in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient.

17. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient.

18. A method for use of lasmiditan in simultaneous, separate, or sequential combination with a calcitonin gene-related peptide (CGRP) antagonist in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient inadequately controlled by lasmiditan or a CGRP antagonist therapy alone.

19. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient inadequately controlled by lasmiditan or galcanezumab therapy alone.

20. A method for use of lasmiditan in simultaneous, separate, or sequential combination with a calcitonin gene-related peptide (CGRP) antagonist in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient suffering from therapy resistant headaches wherein the patients headaches have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

21. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the

group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient suffering from therapy resistant headaches wherein the patients headaches have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

22. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

23. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

24. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once or twice a day.

25. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is

administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

26. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

27. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once or twice a day.

28. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once a day.

29. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once a day.

30. A method for use of lasmiditan in simultaneous, separate, or sequential combination with galcanezumab in the treatment of a headache selected from the

group consisting of episodic headache, chronic headache, chronic cluster headache, or episodic cluster headache in a patient, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.

31. A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of a calcitonin gene-related peptide (CGRP) antagonist.

32. A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab.

33. A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of a calcitonin gene-related peptide (CGRP) antagonist, wherein migraine in the patient was inadequately controlled by lasmiditan or a CGRP antagonist therapy alone.

34. A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab, wherein migraine in the patient was inadequately controlled by lasmiditan or galcanezumab therapy alone.

35. A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of a calcitonin gene-related peptide (CGRP) antagonist, wherein the patient suffers from therapy resistant migraine wherein the patients migraines

have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

36. A method of treating migraine in a patient, comprising administering simultaneously, separately, or sequentially to a patient in need of such a treatment, an effective amount of lasmiditan in combination with an effective amount of galcanezumab, wherein the patient suffers from therapy resistant migraine wherein the patients migraines have been refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

37. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

38. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

39. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered in an initial loading dose of 240 mg of followed by a monthly maintenance dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once or twice a day.

40. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once or twice a day.

41. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once or twice a day.

42. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once or twice a day.

43. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 50 mg once a day.

44. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 100 mg once a day.

45. The method of any one of claims 32, 34, or 36, wherein galcanezumab is administered at a monthly dose of 120 mg, and lasmiditan is administered at a dose of 200 mg once a day.